Immunetune joins the fight against Sars-CoV-2

May 7, 2020

Within a newly established consortium, Immunetune will develop enhanced DNA vaccines against SARS-CoV-2 and other human coronaviruses. The vaccine is built on the combination of two strong synthetic vaccine platforms and the inclusion of conserved T and B cell epitopes to provide both humoral and cellular defenses against Covid-19 and possible future outbreaks of coronaviruses. The consortium is financially supported by Health Holland.

BIO-Europe, 25-28 October 2021

BIO-Europe, 25-28 October 2021

BIO-Europe, 25-28 October 2021 Sijme Zeilemaker, CEO of Immunetune, will be attending BIO-Europe, taking place October 25-28, 2021, in digital format. Feel free to reach out to us to set up a meeting and explore collaboration and investment opportunities. E-mail:...

read more
World Vaccine Congress Europe, 19-21 October 2021

World Vaccine Congress Europe, 19-21 October 2021

World Vaccine Congress Europe, 19-21 October 2021 Gerben Zondag, Founder & COO of Immunetune, will be attending the World Vaccine Congress Europe, taking place October 19-21, 2021, in Barcelona, Spain. Feel free to reach out to us to set up a meeting and explore...

read more